Celtaxsys, Inc. Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation  
1/3/2013 9:49:44 AM

SAN FRANCISCO--(BUSINESS WIRE)--Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).